Aromatase inhibitor strategies in metastatic breast cancer
Heather L McArthur, Patrick G MorrisBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: Despite ongoing therapeutic innovations, metastatic breast cancer (MBC) remains a treatable but incurable disease. In the developed world, a...
Saved in:
Main Authors: | Heather L McArthur (Author), Patrick G Morris (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2009-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical utilities of aromatase inhibitors in breast cancer
by: Chumsri S
Published: (2015) -
Long-term safety of aromatase inhibitors in the treatment of breast cancer
by: Jean-Marc A Nabholtz
Published: (2008) -
What influences aromatase inhibitor continuation intention among breast cancer survivors?
by: Young Kyung Seo, et al.
Published: (2021) -
Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
by: Li Y, et al.
Published: (2020) -
Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
by: Maha F. Althuwaibi, et al.
Published: (2023)